 |
23 Diseases |  |
7 Trials |
|
7 Trials |  |
302 News |  |
| «123456» |
- emtricitabine / Generic mfg.
[VIRTUAL] PrEP initiation, persistence, and HIV seroconversion rates in African adolescent girls and young women (AGYW) from Kenya and South Africa: The POWER demonstration project () - Feb 7, 2021 - Abstract #HIVR4P2021HIVR4P_280;
Although only a fifth persisted with PrEP through 6 months, one-quarter restarted PrEP, suggesting that women can recognize when they need PrEP. Strategies to simplify PrEP delivery, support adherence and/or provide different PrEP options for African AGYW could improve persistence and protection.
- | Biomarker, Journal, Next-generation sequencing: HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform. (Pubmed Central) - Feb 2, 2021
The NGS represent a promising tool for the accurate detection of DRMs of CRF-35AD that is dominant subtype in Iranian HIV-1 infected population and for the first time revealed HIV-1 subtype G in Iranian population. In the present study polymorphic mutation in the position of K20R, M36I, H69K, L89 M were properly reported in CRF35AD that is dominant in Iranian HIV patients.
- | tenofovir disoproxil fumarate / Generic mfg., emtricitabine / Generic mfg.
Journal: Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men. (Pubmed Central) - Jan 29, 2021
STI rates were high but stable among high-risk MSM while taking PrEP, compared with a high but increasing trend in STI positivity before commencing PrEP. These findings suggest the importance of considering trends in STIs when describing how PrEP use may be associated with STI incidence.
- || Vemlidy (tenofovir alafenamide) / Gilead, Tyzeka (telbivudine) / Novartis
Retrospective data, Review, Journal: Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. (Pubmed Central) - Jan 15, 2021
Peripartum antiviral prophylaxis is highly effective at reducing the risk of HBV MTCT. Our findings support the 2020 WHO recommendation of administering antivirals during pregnancy, specifically tenofovir disoproxil fumarate, for the prevention of HBV MTCT.
- | New trial: ARTAN-C19: Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 (clinicaltrials.gov) - Jan 14, 2021
P=N/A, N=219, Recruiting, Sponsor: Universidade Federal do Ceara
- | Journal: Antiretroviral Drugs Associated with Subclinical Coronary Artery Disease in the Swiss HIV Cohort Study. (Pubmed Central) - Jan 8, 2021
An increased risk of non-calcified/mixed plaque was only found in patients exposed to abacavir. Emtricitabine was negatively associated with non-calcified/mixed plaque, while tenofovir disoproxil fumarate and efavirenz were negatively associated with any plaque and calcified plaque, respectively.
- | emtricitabine / Generic mfg.
Journal: Quantitative Analysis of Emtricitabine in Dosage Forms Using Green RP-HPTLC and Routine NP-HPTLC Methods-A Contrast of Validation Parameters. (Pubmed Central) - Jan 7, 2021
Accordingly, the green densitometry technique was found to be better than the routine densitometry technique for ECT assays. Thus, the green densitometry technique can be successfully applied for the quantitation of ECT in the marketed formulations.
- || Selzentry (maraviroc) / ViiV Healthcare
Clinical, Journal: A Translational Approach to Predicting the Efficacy of Maraviroc-based Regimens as HIV Pre-exposure Prophylaxis. (Pubmed Central) - Jan 6, 2021
Poor adherence resulted in drastic decrease in efficacy in the FGT but not colorectal tissue. However, greater forgiveness was seen when maraviroc was combined with tenofovir or emtricitabine, suggesting that maraviroc should not be used alone as PrEP.
- | Vemlidy (tenofovir alafenamide) / Gilead
Journal: Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. (Pubmed Central) - Jan 5, 2021
FTC-TP was quantifiable for up to 1 week after drug cessation. Together, these moieties provide complementary measures of cumulative adherence and recent dosing for TAF/FTC.
- | emtricitabine / Generic mfg.
Journal: Solubility, Hansen Solubility Parameters and Thermodynamic Behavior of Emtricitabine in Various (Polyethylene Glycol-400 + Water) Mixtures: Computational Modeling and Thermodynamics. (Pubmed Central) - Dec 30, 2020
"Apparent thermodynamic analysis" showed an "endothermic and entropy-driven dissolution" of ECT in all "PEG-400 + water" combinations studied. The solvation nature of ECT was found an "enthalpy-driven" in each "PEG-400 + water" mixture studied.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Repurposing Nucleoside Analogs for Human Coronaviruses. (Pubmed Central) - Dec 30, 2020
Here, we evaluated a panel compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance sofosbuvir demonstrated no antiviral effect against CoV-2 and its triphosphate did not inhibit CoV-2 RNA polymerase.
- || Review, Journal: Prescribing pre-exposure prophylaxis for HIV. (Pubmed Central) - Dec 29, 2020
Of significance sofosbuvir demonstrated no antiviral effect against CoV-2 and its triphosphate did not inhibit CoV-2 RNA polymerase. No abstract available
- || Review, Journal: Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. (Pubmed Central) - Dec 17, 2020
Strategies to achieve this goal should include educational interventions, innovative approaches to delivery of HIV care, financial support, and destigmatization of PrEP and PrEP users. Until then, PrEP uptake will continue to be suboptimal, particularly among those who need it most.
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, Crixivan (indinavir sulfate) / Merck (MSD)
Retrospective data, Journal: A retrospective descriptive investigation of adult patients receiving third-line antiretroviral therapy in the North West province, South Africa. (Pubmed Central) - Dec 15, 2020
This study support the need for earlier resistance testing. It firstly reported on time duration post diagnosis on various ART regimens and secondly resistance patterns of adults before TLART was initiated in these districts.
- || Vemlidy (tenofovir alafenamide) / Gilead
Review, Journal: Investigational drugs with dual activity against HBV and HIV (Review). (Pubmed Central) - Dec 3, 2020
Therefore, it is necessary to develop more drugs with dual activity against HBV and HIV. The present review outlines the mechanisms, safety and efficacy of certain drugs that have been investigated for this purpose.
- | Sovaldi (sofosbuvir) / Gilead, Vemlidy (tenofovir alafenamide) / Gilead
Journal: Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. (Pubmed Central) - Dec 1, 2020
These results provide a molecular basis for inhibition of the SARS-CoV-2 RdRp by these nucleotide analogues. If sufficient efficacy of some of these FDA-approved drugs in inhibiting viral replication in cell culture is established, they may be explored as potential COVID-19 therapeutics.
- | Selzentry (maraviroc) / ViiV Healthcare
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) (clinicaltrials.gov) - Nov 6, 2020
P4, N=38, Terminated, Sponsor: Giovanni Di Perri
If sufficient efficacy of some of these FDA-approved drugs in inhibiting viral replication in cell culture is established, they may be explored as potential COVID-19 therapeutics. N=76 --> 38 | Trial completion date: Jan 2020 --> Jun 2020 | Recruiting --> Terminated | Trial primary completion date: Jan 2020 --> Jun 2020; Sloww accrual and COVID-19 related problems (impossible to perform LPs)
- | Trial initiation date: LINE-AD: Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD (clinicaltrials.gov) - Nov 2, 2020
P1, N=35, Not yet recruiting, Sponsor: Butler Hospital
N=76 --> 38 | Trial completion date: Jan 2020 --> Jun 2020 | Recruiting --> Terminated | Trial primary completion date: Jan 2020 --> Jun 2020; Sloww accrual and COVID-19 related problems (impossible to perform LPs) Initiation date: Sep 2020 --> Jan 2021
- || Hengmu (tenofovir amibufenamide) / Jiangsu Hansoh Pharma
Trial completion, Trial completion date: Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine (clinicaltrials.gov) - Sep 30, 2020
P1, N=36, Completed, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Initiation date: Sep 2020 --> Jan 2021 Trial completion date: Dec 2020 --> Sep 2020 | Not yet recruiting --> Completed
- | New P1 trial: LINE-AD: Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD (clinicaltrials.gov) - Aug 5, 2020
P1, N=35, Not yet recruiting, Sponsor: Butler Hospital
- || Hengmu (tenofovir amibufenamide) / Jiangsu Hansoh Pharma
New P1 trial: Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine (clinicaltrials.gov) - Jul 20, 2020
P1, N=36, Not yet recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- | emtricitabine / Generic mfg.
Journal: Emtricitabine. (Pubmed Central) - Jul 16, 2020
The methods investigated include identification test, Spectroscopy, chromatography, electrochemicals, and Thermal. Beside the analytical profile, the degradation and stability of Emtricitabine, its pharmacology and pharmacokinetics, Pharmaceutical Applications, Mechanism of Action, dosage forms and dose, ADME profile, and interactions have been debated.
- | Journal: Influence of hair treatments on detection of antiretrovirals by mass spectrometry imaging. (Pubmed Central) - May 19, 2020
While FTC was undetectable in the treated portion of these hair strands, ARVs coadministered with FTC remained detectable in hair strands after treatment. We conclude that IR-MALDESI MSI can be used when measuring adherence to ARV therapy, provided that ARVs other than FTC are targeted in people using hair treatments.
- |||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg., emtricitabine / Generic mfg.
Not to diminish what I hope will prove to be effective therapy, but for the record, tenofovir came from the Czech Republic, Emtriva from NC-based Triangle, to make the HIV combo backbone Truvada. The HCV backbone is from NJ-based Pharmasset. (Twitter) - Apr 11, 2020
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Trial completion date, Trial primary completion date: Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients (clinicaltrials.gov) - Feb 5, 2020
P4, N=20, Active, not recruiting, Sponsor: Fundacion Clinic per a la Recerca Biom
We conclude that IR-MALDESI MSI can be used when measuring adherence to ARV therapy, provided that ARVs other than FTC are targeted in people using hair treatments. Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jul 2020
- | Edurant (rilpivirine) / J&J
Trial completion date: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Jan 22, 2020
P2, N=61, Recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jul 2020 Trial completion date: Aug 2027 --> Aug 2022
- ||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg., emtricitabine / Generic mfg., lamivudine / Generic mfg.
[Amateur opinion] abnormal dreams not seen in PrEP studies, persists in Truvada PI as artifact from Emtriva (FTC) studies w/ EFV or other NNRTI/PI. Minimal diff 3TC vs FTC (Emtriva label p. 7) (Twitter) - Jan 8, 2020
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - Dec 19, 2019
P4, N=300, Recruiting, Sponsor: Kirby Institute
Trial completion date: Aug 2027 --> Aug 2022 Not yet recruiting --> Recruiting
- || Edurant (rilpivirine) / J&J
Trial primary completion date: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Nov 20, 2019
P2, N=61, Recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2020 --> Aug 2022
- | emtricitabine / Generic mfg.
Trial completion: TRANSViiV: Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women (clinicaltrials.gov) - Aug 8, 2019
P4, N=60, Completed, Sponsor: The Huesped Foundation
Trial primary completion date: Jan 2020 --> Aug 2022 Active, not recruiting --> Completed
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - May 24, 2019
P4, N=300, Not yet recruiting, Sponsor: Kirby Institute
Active, not recruiting --> Completed Initiation date: Apr 2019 --> Jul 2019
- | Selzentry (maraviroc) / ViiV Healthcare
Trial completion date, Trial primary completion date: Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) (clinicaltrials.gov) - Apr 22, 2019
P4, N=76, Recruiting, Sponsor: Giovanni Di Perri
Initiation date: Apr 2019 --> Jul 2019 Trial completion date: Mar 2019 --> Jan 2020 | Trial primary completion date: Nov 2018 --> Jan 2020
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - Feb 7, 2019
P4, N=300, Not yet recruiting, Sponsor: Kirby Institute
Trial completion date: Mar 2019 --> Jan 2020 | Trial primary completion date: Nov 2018 --> Jan 2020 Initiation date: Jan 2019 --> Apr 2019
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - Sep 18, 2018
P4, N=300, Not yet recruiting, Sponsor: Kirby Institute
- || emtricitabine / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: TRANSViiV: Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women (clinicaltrials.gov) - Aug 3, 2018
P4, N=60, Active, not recruiting, Sponsor: The Huesped Foundation
Initiation date: Jan 2019 --> Apr 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Jul 2019 | Trial primary completion date: Oct 2017 --> May 2019
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial initiation date: Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients (clinicaltrials.gov) - Aug 1, 2018
P4, N=20, Recruiting, Sponsor: Fundacion Clinic per a la Recerca Biom
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Jul 2019 | Trial primary completion date: Oct 2017 --> May 2019 Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Apr 2018
- || Edurant (rilpivirine) / J&J
Trial completion date, IO biomarker: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Mar 30, 2018
P2, N=61, Recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Apr 2018 Trial completion date: Jun 2024 --> Sep 2027
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients (clinicaltrials.gov) - Dec 4, 2017
P4, N=20, Not yet recruiting, Sponsor: Fundacion Clinic per a la Recerca Biom
- | efavirenz / Generic mfg., didanosine / Generic mfg., emtricitabine / Generic mfg.
Trial completion, Combination therapy: Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs (clinicaltrials.gov) - Oct 16, 2017
P1/2, N=43, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Jun 2024 --> Sep 2027 Active, not recruiting --> Completed
- || emtricitabine / Generic mfg.
Trial primary completion date: TRANSViiV: Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women (clinicaltrials.gov) - Aug 10, 2017
P4, N=60, Recruiting, Sponsor: The Huesped Foundation
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Oct 2017
- | Selzentry (maraviroc) / ViiV Healthcare
New P4 trial: Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) (clinicaltrials.gov) - May 23, 2017
P4, N=76, Recruiting, Sponsor: Giovanni Di Perri
- | emtricitabine / Generic mfg.
Trial completion, Trial primary completion date: Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine (clinicaltrials.gov) - Feb 23, 2017
P2, N=50, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Mar 2017 --> Oct 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2020 --> Feb 2017
- ||||| emtricitabine / Generic mfg.
New P4 trial: TRANSViiV: Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women (clinicaltrials.gov) - Jan 30, 2017
P4, N=60, Recruiting, Sponsor: The Huesped Foundation
- || Edurant (rilpivirine) / J&J
Trial primary completion date, IO biomarker: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Aug 24, 2016
P2, N=56, Recruiting, Sponsor: Janssen Sciences Ireland UC
Active, not recruiting --> Completed | Trial primary completion date: Dec 2020 --> Feb 2017 Trial primary completion date: Oct 2023 --> Jan 2020
- |||| Edurant (rilpivirine) / J&J
Enrollment open, Trial primary completion date, IO biomarker: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Feb 22, 2016
P2, N=56, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial primary completion date: Oct 2023 --> Jan 2020 Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2014 --> Oct 2023
- ||| Edurant (rilpivirine) / J&J
Enrollment change, IO biomarker: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Nov 17, 2015
P2, N=56, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2014 --> Oct 2023 N=36 --> 56
- Fuzeon (enfuvirtide) / Roche
Trial primary completion date: Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=19, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=36 --> 56 Trial primary completion date: May 2008 --> Dec 2007
- Isentress (raltegravir) / Merck (MSD)
Enrollment change, Trial termination: Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals (clinicaltrials.gov) - Jun 8, 2015
P=N/A, N=3, Terminated, Sponsor: University of California, San Diego
Trial primary completion date: May 2008 --> Dec 2007 N=15 --> 3 | Recruiting --> Terminated; Did not meet enrollment goals
- | Fuzeon (enfuvirtide) / Roche
Trial completion: Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (clinicaltrials.gov) - May 31, 2015
P=N/A, N=19, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=15 --> 3 | Recruiting --> Terminated; Did not meet enrollment goals Active, not recruiting --> Completed
- | emtricitabine / Generic mfg.
New P4 trial: Emtricitabine for Naive Chinese Chronic Hepatitis B Patients (clinicaltrials.gov) - Dec 30, 2014
P4, N=2000, Not yet recruiting, Sponsor: Asian-Pacific Alliance of Liver Disease, Beijing